Assembly Biosciences (ASMB)

$27.52 +0.18 (0.66%)
Market Cap 443.03M
Revenue (ttm) 28.52M
Net Income (ttm) -40.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -140.88%
Debt to Equity Ratio 0.00
Volume 102,000
Avg Vol 137,038
Day's Range N/A - N/A
Shares Out 15.82M
Stochastic %K 22%
Beta 1.14
Analysts Strong Sell
Price Target $45.80

Company Profile

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5336 and ABI-1179, which are in Phase 1a/1b clinical studies for recurrent genital herpes; ABI-4334, a capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus that is in Phase 1b clinical study; and ABI-6250, an orally bioavailable hepatitis delta...

Industry: Biotechnology
Sector: Healthcare
Phone: 833 509 4583
Address:
Two Tower Place, 7th Floor, South San Francisco, United States
Stronx
Stronx Jan. 27 at 7:56 PM
$ASMB come on, been walking down for s month now. Time to get back up and above 40$šŸ’„
0 Ā· Reply
ShinnosukeNohara
ShinnosukeNohara Jan. 21 at 2:42 PM
$ASMB this stock is getting completely destroyed in the next time unfortunately.. Volume is low af RIP
1 Ā· Reply
Marc_bullish
Marc_bullish Jan. 20 at 9:01 PM
$ASMB whyyyyyy -30% since nov.
1 Ā· Reply
BigGrinch
BigGrinch Jan. 20 at 8:33 PM
$ASMB is this thing done? Back from over 40
0 Ā· Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 16 at 5:44 PM
$ASMB RSI: 33.68, MACD: -0.9839 Vol: 1.69, MA20: 32.45, MA50: 34.11 āšŖ HOLD - Sideways šŸ‘‰ https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
1 Ā· Reply
ShinnosukeNohara
ShinnosukeNohara Jan. 16 at 4:27 AM
J.P. Morgan Notebook: Big Pharmas Weigh In On Vaccines, AI And MFN $ASMB https://insights.citeline.com/scrip/conferences/jp-morgan/jp-morgan-notebook-big-pharmas-weigh-in-on-vaccines-ai-and-mfn-GTCL42C5BNB2HNC47USU6IYRW4/
0 Ā· Reply
ShinnosukeNohara
ShinnosukeNohara Jan. 15 at 6:10 PM
$ASMB some are panicking. thatā€™s exactly what they wantšŸ˜„
0 Ā· Reply
ShinnosukeNohara
ShinnosukeNohara Jan. 8 at 7:21 PM
$ASMB
0 Ā· Reply
Stronx
Stronx Jan. 7 at 9:38 AM
$ASMB
0 Ā· Reply
ShinnosukeNohara
ShinnosukeNohara Jan. 7 at 9:07 AM
$ASMB time to act faster $GILD $GSK https://www.webullapp.com/news-detail/14159978230416384?theme=1&hl=en&color=2&_v=1&tickerId=913323416&disSymbol=IONS&sourcePage=Stock_NewsList&sp=0&hl=en
0 Ā· Reply
Latest News on ASMB
Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes

Dec 22, 2025, 8:00 AM EST - 5 weeks ago

Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes

GILD

Assembly Biosciences, Inc. (ASMB) Discusses Positive Interim Results for ABI-1179 and ABI-5366 in Recurrent Genital Herpes Phase 1b Studies Transcript

Dec 8, 2025, 8:37 PM EST - 7 weeks ago

Assembly Biosciences, Inc. (ASMB) Discusses Positive Interim Results for ABI-1179 and ABI-5366 in Recurrent Genital Herpes Phase 1b Studies Transcript

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes

Dec 8, 2025, 4:05 PM EST - 7 weeks ago

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes

Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates

Nov 10, 2025, 4:05 PM EST - 2 months ago

Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates

Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver MeetingĀ®

Nov 7, 2025, 8:00 AM EST - 2 months ago

Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver MeetingĀ®

Assembly Biosciences Announces Upcoming Investor Conference Participation

Oct 14, 2025, 7:00 AM EDT - 3 months ago

Assembly Biosciences Announces Upcoming Investor Conference Participation

Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe

Oct 10, 2025, 8:00 AM EDT - 3 months ago

Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe

4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals

Sep 29, 2025, 7:11 AM EDT - 4 months ago

4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals

ARWR ATRA CORT

Assembly Biosciences: Positive Data Of ABI-5366 Brings 2 Fall Program Catalysts

Aug 8, 2025, 4:54 PM EDT - 6 months ago

Assembly Biosciences: Positive Data Of ABI-5366 Brings 2 Fall Program Catalysts

Assembly Biosciences Announces Pricing of $175 Million in Equity Financings

Aug 8, 2025, 8:05 AM EDT - 6 months ago

Assembly Biosciences Announces Pricing of $175 Million in Equity Financings

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes

Aug 8, 2025, 8:00 AM EDT - 6 months ago

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes

Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates

Aug 6, 2025, 4:05 PM EDT - 6 months ago

Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates

Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

Aug 6, 2025, 4:05 PM EDT - 6 months ago

Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop

Jul 26, 2025, 3:00 AM EDT - 6 months ago

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop

Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179

Jun 30, 2025, 8:00 AM EDT - 7 months ago

Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179

Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B

Jun 25, 2025, 8:00 AM EDT - 7 months ago

Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B

Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference

May 27, 2025, 4:05 PM EDT - 8 months ago

Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference

Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates

May 8, 2025, 4:05 PM EDT - 9 months ago

Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates

New Preclinical Data for Assembly Biosciences' Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 Presented at the EASL Congress 2025

May 7, 2025, 8:00 AM EDT - 9 months ago

New Preclinical Data for Assembly Biosciences' Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 Presented at the EASL Congress 2025

Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress

Apr 9, 2025, 2:00 AM EDT - 10 months ago

Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress

Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights

Mar 20, 2025, 4:05 PM EDT - 11 months ago

Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights

Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

Feb 26, 2025, 8:00 AM EST - 11 months ago

Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes

Feb 20, 2025, 8:00 AM EST - 1 year ago

Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes

Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

Dec 26, 2024, 8:00 AM EST - 1 year ago

Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop

Jul 15, 2024, 8:00 AM EDT - 1 year ago

Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop

Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366

Jun 10, 2024, 8:00 AM EDT - 1 year ago

Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366

Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congressā„¢ 2024

May 22, 2024, 8:00 AM EDT - 1 year ago

Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congressā„¢ 2024

Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights

May 8, 2024, 4:05 PM EDT - 1 year ago

Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights

Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights

Mar 28, 2024, 4:05 PM EDT - 1 year ago

Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights

Assembly Biosciences Announces Effective Date of Reverse Stock Split

Feb 8, 2024, 8:00 AM EST - 2 years ago

Assembly Biosciences Announces Effective Date of Reverse Stock Split

Assembly Biosciences Provides Anticipated Development Milestones for 2024

Jan 4, 2024, 8:00 AM EST - 2 years ago

Assembly Biosciences Provides Anticipated Development Milestones for 2024

Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 10, 2023, 4:05 PM EST - 2 years ago

Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer

Nov 8, 2023, 8:00 AM EST - 2 years ago

Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer

Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases

Oct 17, 2023, 7:00 AM EDT - 2 years ago

Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases

GILD

Assembly Biosciences to Present New Data at AASLD The Liver MeetingĀ®

Oct 11, 2023, 8:00 AM EDT - 2 years ago

Assembly Biosciences to Present New Data at AASLD The Liver MeetingĀ®

Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor

Oct 2, 2023, 8:00 AM EDT - 2 years ago

Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor

Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting

Sep 19, 2023, 4:05 PM EDT - 2 years ago

Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting

Assembly Biosciences Presents New Data Highlighting Herpes Simplex Virus Development Candidate ABI-5366 at the 47th Annual International Herpesvirus Workshop

Jul 17, 2023, 8:00 AM EDT - 2 years ago

Assembly Biosciences Presents New Data Highlighting Herpes Simplex Virus Development Candidate ABI-5366 at the 47th Annual International Herpesvirus Workshop

Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL International Liver Congressā„¢ 2023

Jun 7, 2023, 8:00 AM EDT - 2 years ago

Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL International Liver Congressā„¢ 2023

Assembly Biosciences to Present During the 2023 Jefferies Healthcare Conference

May 23, 2023, 4:05 PM EDT - 2 years ago

Assembly Biosciences to Present During the 2023 Jefferies Healthcare Conference

Assembly Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights

May 4, 2023, 4:05 PM EDT - 2 years ago

Assembly Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights

Assembly Biosciences Provides Update on its Core Inhibitor Pipeline, Reports Fourth Quarter and Year End 2022 Financial Results and Recent Highlights

Mar 22, 2023, 4:05 PM EDT - 3 years ago

Assembly Biosciences Provides Update on its Core Inhibitor Pipeline, Reports Fourth Quarter and Year End 2022 Financial Results and Recent Highlights

Carver Biosciences Announces Appointment of Three Members to its Scientific Advisory Board

Jan 17, 2023, 7:00 AM EST - 3 years ago

Carver Biosciences Announces Appointment of Three Members to its Scientific Advisory Board

Assembly Biosciences Presents New Data at AASLD The Liver MeetingĀ® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV

Nov 4, 2022, 8:00 AM EDT - 3 years ago

Assembly Biosciences Presents New Data at AASLD The Liver MeetingĀ® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV

Assembly Biosciences to Present Data in Four Poster Presentations at Upcoming AASLD The Liver MeetingĀ®

Oct 24, 2022, 8:00 AM EDT - 3 years ago

Assembly Biosciences to Present Data in Four Poster Presentations at Upcoming AASLD The Liver MeetingĀ®

Assembly Bio Announces Retirement of John G. McHutchison, AO, MD as CEO and Appoints Current President and COO Jason A.

Oct 5, 2022, 4:05 PM EDT - 3 years ago

Assembly Bio Announces Retirement of John G. McHutchison, AO, MD as CEO and Appoints Current President and COO Jason A.

Assembly Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights

Aug 9, 2022, 4:05 PM EDT - 3 years ago

Assembly Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights

Assembly Biosciences Announces Program Reprioritization and Organizational Update

Jul 20, 2022, 4:05 PM EDT - 3 years ago

Assembly Biosciences Announces Program Reprioritization and Organizational Update

Assembly Biosciences Presents New Data Highlighting Clinical Progress of Core Inhibitor Programs at EASL's International Liver Congressā„¢ 2022

Jun 22, 2022, 8:00 AM EDT - 3 years ago

Assembly Biosciences Presents New Data Highlighting Clinical Progress of Core Inhibitor Programs at EASL's International Liver Congressā„¢ 2022

Assembly Biosciences to Introduce New Small Molecule Liver-Focused Interferon-Ī± Receptor Agonist Research Program in Webcast on July 26, 2022

Jun 21, 2022, 8:00 AM EDT - 3 years ago

Assembly Biosciences to Introduce New Small Molecule Liver-Focused Interferon-Ī± Receptor Agonist Research Program in Webcast on July 26, 2022

Stronx
Stronx Jan. 27 at 7:56 PM
$ASMB come on, been walking down for s month now. Time to get back up and above 40$šŸ’„
0 Ā· Reply
ShinnosukeNohara
ShinnosukeNohara Jan. 21 at 2:42 PM
$ASMB this stock is getting completely destroyed in the next time unfortunately.. Volume is low af RIP
1 Ā· Reply
Marc_bullish
Marc_bullish Jan. 20 at 9:01 PM
$ASMB whyyyyyy -30% since nov.
1 Ā· Reply
BigGrinch
BigGrinch Jan. 20 at 8:33 PM
$ASMB is this thing done? Back from over 40
0 Ā· Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 16 at 5:44 PM
$ASMB RSI: 33.68, MACD: -0.9839 Vol: 1.69, MA20: 32.45, MA50: 34.11 āšŖ HOLD - Sideways šŸ‘‰ https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
1 Ā· Reply
ShinnosukeNohara
ShinnosukeNohara Jan. 16 at 4:27 AM
J.P. Morgan Notebook: Big Pharmas Weigh In On Vaccines, AI And MFN $ASMB https://insights.citeline.com/scrip/conferences/jp-morgan/jp-morgan-notebook-big-pharmas-weigh-in-on-vaccines-ai-and-mfn-GTCL42C5BNB2HNC47USU6IYRW4/
0 Ā· Reply
ShinnosukeNohara
ShinnosukeNohara Jan. 15 at 6:10 PM
$ASMB some are panicking. thatā€™s exactly what they wantšŸ˜„
0 Ā· Reply
ShinnosukeNohara
ShinnosukeNohara Jan. 8 at 7:21 PM
$ASMB
0 Ā· Reply
Stronx
Stronx Jan. 7 at 9:38 AM
$ASMB
0 Ā· Reply
ShinnosukeNohara
ShinnosukeNohara Jan. 7 at 9:07 AM
$ASMB time to act faster $GILD $GSK https://www.webullapp.com/news-detail/14159978230416384?theme=1&hl=en&color=2&_v=1&tickerId=913323416&disSymbol=IONS&sourcePage=Stock_NewsList&sp=0&hl=en
0 Ā· Reply
Zonata
Zonata Jan. 7 at 1:58 AM
$ASMB key areas for retracement. No bad news, so it should be a great time to buy back shares. The story is intact and the news were peachy.
0 Ā· Reply
Poldi2021
Poldi2021 Jan. 6 at 8:20 PM
$ASMB huge buy of 17.000 Shows šŸ‘šŸ‘
1 Ā· Reply
Poldi2021
Poldi2021 Jan. 6 at 8:18 PM
$ASMB yeah do it..have a great timešŸ‘
0 Ā· Reply
ShinnosukeNohara
ShinnosukeNohara Jan. 6 at 8:16 PM
$ASMB Short it till next MondayšŸ˜„
0 Ā· Reply
ShinnosukeNohara
ShinnosukeNohara Jan. 6 at 6:30 PM
$ASMB Gilead executives right now..
1 Ā· Reply
Jkwran69
Jkwran69 Jan. 6 at 5:57 PM
$ASMB we've had good news lately so why the daily drops in SP?
1 Ā· Reply
DummiesNixGerafft
DummiesNixGerafft Jan. 6 at 3:17 PM
Customer first, all information exclusively for our NGC members. Ach ne warte, nur wer noch ne extra GebĆ¼hr bezahlt, bekommt beim SD Verein alle Infos. lol. Was einen da erreicht ist ja unfassbar. Es gibt jetzt einen NGC+ šŸ¤£ wohl nur ein paar Tausender extra. Geheimtipp $ASMB -50%
0 Ā· Reply
ShinnosukeNohara
ShinnosukeNohara Dec. 30 at 8:04 PM
$ASMB
0 Ā· Reply
BillionerOfKing
BillionerOfKing Dec. 30 at 1:53 AM
$ASMB Current Stock Price: $33.44 Contracts to trade: $35 ASMB Jan 16 2026 Call Entry: $0.50 Exit: $0.83 ROI: 66% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 Ā· Reply
jjokerst
jjokerst Dec. 27 at 6:45 PM
$GILD and $ASMB are co opting research for HSV-1 and HSV-2 (herpes) cure. Recent results showing highly antiviral activity with 94% reduction in results compared to placebo.
0 Ā· Reply
DLTT4489
DLTT4489 Dec. 26 at 5:39 PM
$ASMB holding nice šŸ‘Œ šŸ‘
0 Ā· Reply
ShinnosukeNohara
ShinnosukeNohara Dec. 26 at 2:12 PM
$ASMB 2 A.I. generated bullshit messages below mešŸ˜„
1 Ā· Reply